Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | GPR39 | O43194 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | SMO | Q99835 | 3/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287978 | 0.85 | DRD2 (0.53) | RETHTR7GPR39PDE3BPDE3A | |
| SCHEMBL15271400 | 0.82 | GAA (0.52) | HTR7GPR39PDE3BPDE3APANK3 | |
| SCHEMBL2828952 | 0.82 | SMO (0.53) | HTR7GPR39PDE3BPDE3APANK3 | |
| SCHEMBL26292614 | 0.82 | RET (0.56) | RETTIPARPHTR7GPR39PDE3B | |
| SCHEMBL14924445 | 0.81 | DRD2 (0.56) | RETHTR7PANK3ALDH1A1L3MBTL1 | |
| SCHEMBL19748777 | 0.81 | DRD2 (0.50) | TIPARPHTR7GPR39PDE3BPDE3A | |
| SCHEMBL21521157 | 0.80 | HTR7 (0.50) | TIPARPHTR7GPR39PDE3BPDE3A | |
| SCHEMBL3592250 | 0.80 | KDM4E (0.54) | HTR7PANK3SMOKDM4EALDH1A1 | |
| SCHEMBL3398177 | 0.80 | TLR7 (0.46) | RETHTR7 | |
| SCHEMBL26291417 | 0.80 | TIPARP (0.54) | RETTIPARPHTR7GPR39PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | RET 3307/4885TIPARP 37/4885HTR7 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.